279
Views
18
CrossRef citations to date
0
Altmetric
Review

Longer acting GLP-1 receptor agonists and the potential for improved cardiovascular outcomes: a review of current literature

, &
Pages 247-259 | Published online: 10 Jan 2014

Keep up to date with the latest research on this topic with citation updates for this article.

Read on this site (1)

Bin Yang, Ana Gomes Dos Santos, Sanyogitta Puri, Annette Bak & Liping Zhou. (2022) The industrial design, translation, and development strategies for long-acting peptide delivery. Expert Opinion on Drug Delivery 19:10, pages 1233-1245.
Read now

Articles from other publishers (17)

Donald J. AbrahamMichael Wagner, Andreas Evers, Martin Bossart & Anish Konkar. 2003. Burger's Medicinal Chemistry and Drug Discovery. Burger's Medicinal Chemistry and Drug Discovery 1 69 .
Valerie D Heuvelman, Daniël H Van Raalte & Mark M Smits. (2020) Cardiovascular effects of glucagon-like peptide 1 receptor agonists: from mechanistic studies in humans to clinical outcomes. Cardiovascular Research 116:5, pages 916-930.
Crossref
Daniel B. Maselli & Michael Camilleri. 2021. Diabetes: from Research to Clinical Practice. Diabetes: from Research to Clinical Practice 171 192 .
Maria Findeisen, Tamara L. Allen, Darren C. Henstridge, Helene Kammoun, Amanda E. Brandon, Laurie L. Baggio, Kevin I. Watt, Martin Pal, Lena Cron, Emma Estevez, Christine Yang, Greg M. Kowalski, Liam O’Reilly, Casey Egan, Emily Sun, Le May Thai, Guy Krippner, Timothy E. Adams, Robert S. Lee, Joachim Grötzinger, Christoph Garbers, Steve Risis, Michael J. Kraakman, Natalie A. Mellet, James Sligar, Erica T. Kimber, Richard L. Young, Michael A. Cowley, Clinton R. Bruce, Peter J. Meikle, Paul A. Baldock, Paul Gregorevic, Trevor J. Biden, Gregory J. Cooney, Damien J. Keating, Daniel J. Drucker, Stefan Rose-John & Mark A. Febbraio. (2019) Treatment of type 2 diabetes with the designer cytokine IC7Fc. Nature 574:7776, pages 63-68.
Crossref
Yaohao Li, Kimberly A. Clark & Zhongping Tan. (2018) Methods for engineering therapeutic peptides. Chinese Chemical Letters 29:7, pages 1074-1078.
Crossref
Yanan Shi, Xinfeng Sun, Liping Zhang, Kaoxiang Sun, Keke Li, Youxin Li & Qiang Zhang. (2018) Fc-modified exenatide-loaded nanoparticles for oral delivery to improve hypoglycemic effects in mice. Scientific Reports 8:1.
Crossref
Eric L. Schneider, Brian R. Hearn, Samuel J. Pfaff, Ralph Reid, David G. Parkes, Niels Vrang, Gary W. Ashley & Daniel V. Santi. (2017) A Hydrogel-Microsphere Drug Delivery System That Supports Once-Monthly Administration of a GLP-1 Receptor Agonist. ACS Chemical Biology 12:8, pages 2107-2116.
Crossref
A. Palani, Y.-Y. Zhou, M. Halleck & P. Carrington. 2017. Comprehensive Medicinal Chemistry III. Comprehensive Medicinal Chemistry III 481 490 .
Jennifer J. Wright & Tracy S. Tylee. (2016) Pharmacologic Therapy of Type 2 Diabetes. Medical Clinics of North America 100:4, pages 647-663.
Crossref
Eric L. Schneider, Jeff Henise, Ralph Reid, Gary W. Ashley & Daniel V. Santi. (2016) Hydrogel Drug Delivery System Using Self-Cleaving Covalent Linkers for Once-a-Week Administration of Exenatide. Bioconjugate Chemistry 27:5, pages 1210-1215.
Crossref
Brian A. BaldoBrian A. Baldo. 2016. Safety of Biologics Therapy. Safety of Biologics Therapy 309 400 .
Donna Ryan & Andres Acosta. (2015) GLP ‐1 receptor agonists: Nonglycemic clinical effects in weight loss and beyond . Obesity 23:6, pages 1119-1129.
Crossref
Amanda R. Vest. (2014) Incretin-Related Drug Therapy in Heart Failure. Current Heart Failure Reports 12:1, pages 24-32.
Crossref
Sanjoy K Paul, Kerenaftali Klein, David Maggs & Jennie H Best. (2015) The association of the treatment with glucagon-like peptide-1 receptor agonist exenatide or insulin with cardiovascular outcomes in patients with type 2 diabetes: a retrospective observational study. Cardiovascular Diabetology 14:1, pages 10.
Crossref
R. V. Scott, T. M. Tan & S. R. Bloom. (2014) Can Bayliss and Starling gut hormones cure a worldwide pandemic?. The Journal of Physiology 592:23, pages 5153-5167.
Crossref
B. Guerci & J.-P. Sauvanet. (2014) Traitement du diabète de type 2 : l’exénatide à libération prolongée. Médecine des Maladies Métaboliques 8:2, pages 189-200.
Crossref
Rachel C. Troke, Tricia M. Tan & Steve R. Bloom. (2013) The future role of gut hormones in the treatment of obesity. Therapeutic Advances in Chronic Disease 5:1, pages 4-14.
Crossref

Reprints and Corporate Permissions

Please note: Selecting permissions does not provide access to the full text of the article, please see our help page How do I view content?

To request a reprint or corporate permissions for this article, please click on the relevant link below:

Academic Permissions

Please note: Selecting permissions does not provide access to the full text of the article, please see our help page How do I view content?

Obtain permissions instantly via Rightslink by clicking on the button below:

If you are unable to obtain permissions via Rightslink, please complete and submit this Permissions form. For more information, please visit our Permissions help page.